Phase I/II trial findings add to growing body of data on acalabrutinib clinical profile

CAMBRIDGE, England - Monday, December 5th 2016 [ME NewsWire]

(BUSINESS WIRE)-- AstraZeneca and its haematology Centre of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat forms of chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.1 The trial includes data from individuals with intolerance to ibrutinib and those with Richter transformation, when CLL transforms into a more aggressive lymphoma.2 Findings were shared with the medical community during two oral presentations at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, USA.

Acerta Pharma Chief Executive Officer, Flavia Borellini, PhD, said: “The data at ASH further validate previous clinical trial findings and continue to demonstrate t ... Read more »

THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE

NEW YORK - Saturday, December 10th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Twenty-First Century Fox, Inc. (“21st Century Fox”) notes the announcement made today by Sky plc (“Sky”) and confirms that it has reached an agreement in principle in relation to a possible offer (the “Possible Offer”) to acquire all of the outstanding shares in Sky it does not already own at a price of £10.75 per share payable in cash less the value of any dividends subsequently paid by Sky. However, certain material offer terms remain under discussion and the Possible Offer may or may not lead to an offer being made by 21st Century Fox.

The Independent Directors of Sky have indicated to 21st Century Fox that they are willing to recomm ... Read more »